Pfizer appoints Cecile Guegan as its chief financial officer
- US stocks
- Management change
- Health Care

Pfizer (NYSE: PFE) named Cecile Guegan its Chief Financial Officer, effective 1 Nov 2026, with a base salary of $1.3 million a year, and it said on 3 Nov 2026 that the Board had voted for her unanimously. Guegan had been interim Chief Financial Officer since 16 Aug 2026.
Guegan was interim CFO from August
Cecile Guegan became interim Chief Financial Officer effective 16 Aug 2026, and the Board elected her Chief Financial Officer effective 1 Nov 2026. The filing puts her age at 55 and credits her with more than 25 years in global finance at drugmakers.
She joined Pfizer with its 2009 acquisition of Wyeth, where she had been chief financial officer supporting the Asia Pacific and EMEA/Canada businesses. Immediately before her interim appointment, she was Senior Vice President of Finance for Pfizer's Global Biopharmaceuticals business, a role held since 2022.
Her education is a master's in management with an audit and finance focus from the Graduate School of Management of Brest, France, plus a French DECF bachelor's in accounting.
Pay terms are set at $1.3 million
The Compensation Committee unanimously approved an annual base salary of $1.3 million for Guegan as of the effective date. It also approved an annual target cash incentive of $1.3 million, which the filing says equals 100% of her base salary and will be determined based on the salary paid during the year.
Chairman and Chief Executive Officer Albert Bourla said in the release that Guegan knows the company and its industry well. The company said her remit covers the whole finance function, from audit and treasury to investor relations, tax and controllership.
What the CFO change means for Pfizer shareholders
The change concerns who leads Pfizer's finance function. The filing gives no results figures for the period, so it does not show how the appointment affects earnings.
The filing does not say whether Guegan received equity awards, whether her pay changed from the interim role, or why the role changed hands. It gives no further dated step beyond the 1 Nov 2026 effective date.
At a glance
| Item | Detail |
|---|---|
| Name | Cecile Guegan |
| Role | Chief Financial Officer and Executive Vice President |
| Interim CFO from | 16 Aug 2026 |
| Board vote | 3 Nov 2026, unanimous |
| Effective date | 1 Nov 2026 |
| Annual base salary | $1.3 million |
| Annual target cash incentive | $1.3 million, 100% of base salary |
Filed with the US SEC on . Reference: Original filing (SEC)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.
Figures are from the company's filings with the US Securities and Exchange Commission and are in US dollars. Investing in US stocks from India is subject to the Liberalised Remittance Scheme, currency risk and taxes in both countries.
